The U.S. Attorney’s Office is leading the new investigation.
The investigations were launched after a Feb. 10 Seattle Times report uncovered concerns related to surgeons pushing for increased patient volume and a culture of intimidation at SNI. Swedish’s then-CEO, Anthony Armada, stepped down in the wake of the report, as did Johnny Delashaw, MD, the chairman of neurosurgery at SNI.
Guy Hudson, MD, the interim CEO of Swedish, sent a memo to staff Wednesday regarding the newly launched investigation from the U.S. Attorney’s Office. “As with all regulatory reviews, we will cooperate fully to ensure that we are living our values and upholding the highest standards,” he said in the memo, according to the Seattle Times.
A Swedish spokesperson told the Seattle Times she did not know the scope of the federal inquiry or if it was a criminal or civil investigation. Swedish did not immediately respond to a Becker’s request for comment.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
